Eric A Secemsky1, Rebecca Scherzer2, Elaine Nitta3, Alan H B Wu4, David C Lange5, Steven G Deeks6, Jeffrey N Martin7, James Snider8, Peter Ganz3, Priscilla Y Hsue9. 1. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Medicine, Veteran's Affairs Medical Center, San Francisco, University of California-San Francisco, San Francisco, California. 3. Division of Cardiology, Department of Medicine, San Francisco General Hospital, University of California-San Francisco, San Francisco, California. 4. Laboratory Medicine, San Francisco General Hospital, University of California-San Francisco, San Francisco, California. 5. Division of Cardiology, Department of Medicine, Cedars-Sinai Hospital, Los Angeles, California. 6. San Francisco General Hospital HIV/AIDS Division, Department of Medicine, University of California-San Francisco, San Francisco, California. 7. Department of Epidemiology and Biostatistics, University of California-San Francisco and San Francisco General Hospital HIV/AIDS Division, San Francisco, California. 8. Critical Diagnostics, San Diego, California. 9. Division of Cardiology, Department of Medicine, San Francisco General Hospital, University of California-San Francisco, San Francisco, California. Electronic address: phsue@medsfgh.ucsf.edu.
Abstract
OBJECTIVES: This study sought to determine whether biomarkers ST2, growth differentiation factor (GDF)-15, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin I are elevated in patients infected with human immunodeficiency virus (HIV) and are associated with cardiovascular dysfunction and all-cause mortality. BACKGROUND: HIV-infected patients have high rates of cardiovascular disease. Markers of myocardial stress may identify at-risk patients and provide additional prognostic information. METHODS: Biomarkers and echocardiograms were assessed in 332 HIV-infected patients and 50 age- and sex-matched control subjects. Left ventricular systolic dysfunction was defined as ejection fraction <50%, diastolic dysfunction (DD) as stage 1 or higher, and pulmonary hypertension as pulmonary artery systolic pressure ≥35 mm Hg. Mortality data were obtained from the National Death Index. RESULTS: Patients with HIV had a median age of 49 years, and 80% were male. Compared with control subjects, HIV-infected patients had higher adjusted percent estimates of all biomarkers except ST2 and interleukin-6. Among HIV-infected patients, 45% had DD; only ST2 was associated with DD (relative risk [RR]: 1.36; p = 0.047). Left ventricular systolic dysfunction was rare in this cohort (5%). Pulmonary hypertension was present in 27% of HIV-infected patients and was associated with GDF-15 (RR: 1.18; p = 0.04), NT-proBNP (RR: 1.18; p = 0.007), and cystatin C (RR: 1.54; p = 0.03). Thirty-eight deaths occurred among HIV-infected patients over a median of 6.1 years. In adjusted analysis, all-cause mortality was independently predicted by ST2 (hazard ratio [HR]: 2.04; p = 0.010), GDF-15 (HR: 1.42; p = 0.0054), high-sensitivity C-reactive protein (HR: 1.25; p = 0.023), and D-dimer (HR: 1.49; p = 0.029). Relationships were unchanged when analyses were restricted to virally suppressed HIV-infected patients receiving antiretroviral therapy. CONCLUSIONS: Among HIV-infected patients, ST2 and GDF-15 were associated with both cardiovascular dysfunction and all-cause mortality, and these variables may be useful at identifying those at risk for developing cardiovascular events and death.
OBJECTIVES: This study sought to determine whether biomarkers ST2, growth differentiation factor (GDF)-15, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin I are elevated in patients infected with human immunodeficiency virus (HIV) and are associated with cardiovascular dysfunction and all-cause mortality. BACKGROUND:HIV-infectedpatients have high rates of cardiovascular disease. Markers of myocardial stress may identify at-risk patients and provide additional prognostic information. METHODS: Biomarkers and echocardiograms were assessed in 332 HIV-infectedpatients and 50 age- and sex-matched control subjects. Left ventricular systolic dysfunction was defined as ejection fraction <50%, diastolic dysfunction (DD) as stage 1 or higher, and pulmonary hypertension as pulmonary artery systolic pressure ≥35 mm Hg. Mortality data were obtained from the National Death Index. RESULTS:Patients with HIV had a median age of 49 years, and 80% were male. Compared with control subjects, HIV-infectedpatients had higher adjusted percent estimates of all biomarkers except ST2 and interleukin-6. Among HIV-infectedpatients, 45% had DD; only ST2 was associated with DD (relative risk [RR]: 1.36; p = 0.047). Left ventricular systolic dysfunction was rare in this cohort (5%). Pulmonary hypertension was present in 27% of HIV-infectedpatients and was associated with GDF-15 (RR: 1.18; p = 0.04), NT-proBNP (RR: 1.18; p = 0.007), and cystatin C (RR: 1.54; p = 0.03). Thirty-eight deaths occurred among HIV-infectedpatients over a median of 6.1 years. In adjusted analysis, all-cause mortality was independently predicted by ST2 (hazard ratio [HR]: 2.04; p = 0.010), GDF-15 (HR: 1.42; p = 0.0054), high-sensitivity C-reactive protein (HR: 1.25; p = 0.023), and D-dimer (HR: 1.49; p = 0.029). Relationships were unchanged when analyses were restricted to virally suppressed HIV-infectedpatients receiving antiretroviral therapy. CONCLUSIONS: Among HIV-infectedpatients, ST2 and GDF-15 were associated with both cardiovascular dysfunction and all-cause mortality, and these variables may be useful at identifying those at risk for developing cardiovascular events and death.
Authors: Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-07 Impact factor: 5.251
Authors: Nina Friis-Møller; Rodolphe Thiébaut; Peter Reiss; Rainer Weber; Antonella D'Arminio Monforte; Stephane De Wit; Wafaa El-Sadr; Eric Fontas; Signe Worm; Ole Kirk; Andrew Phillips; Caroline A Sabin; Jens D Lundgren; Matthew G Law Journal: Eur J Cardiovasc Prev Rehabil Date: 2010-10
Authors: Bonnie Ky; Benjamin French; Kristin McCloskey; J Eduardo Rame; Erin McIntosh; Puja Shahi; Daniel L Dries; W H Wilson Tang; Alan H B Wu; James C Fang; Rebecca Boxer; Nancy K Sweitzer; Wayne C Levy; Lee R Goldberg; Mariell Jessup; Thomas P Cappola Journal: Circ Heart Fail Date: 2010-12-22 Impact factor: 8.790
Authors: Tibor Kempf; Rüdiger Horn-Wichmann; Georg Brabant; Timo Peter; Tim Allhoff; Gunnar Klein; Helmut Drexler; Nina Johnston; Lars Wallentin; Kai C Wollert Journal: Clin Chem Date: 2006-12-21 Impact factor: 8.327
Authors: Kai C Wollert; Tibor Kempf; Timo Peter; Sylvia Olofsson; Stefan James; Nina Johnston; Bertil Lindahl; Rüdiger Horn-Wichmann; Georg Brabant; Maarten L Simoons; Paul W Armstrong; Robert M Califf; Helmut Drexler; Lars Wallentin Journal: Circulation Date: 2007-02-05 Impact factor: 29.690
Authors: Daniel A Duprez; Jacqueline Neuhaus; Russell Tracy; Lewis H Kuller; Steven G Deeks; Chloe Orkin; Albrecht Stoehr; Ian J Woolley; James D Neaton Journal: AIDS Date: 2011-03-13 Impact factor: 4.177
Authors: Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton Journal: PLoS One Date: 2012-09-10 Impact factor: 3.240
Authors: Nils Nickel; Danny Jonigk; Tibor Kempf; Clemens L Bockmeyer; Lavinia Maegel; Johanna Rische; Florian Laenger; Ulrich Lehmann; Clemens Sauer; Mark Greer; Tobias Welte; Marius M Hoeper; Heiko A Golpon Journal: Respir Res Date: 2011-05-06
Authors: Raza M Alvi; Maryam Afshar; Anne M Neilan; Noor Tariq; Malek Hassan; Jaime Gerber; Magid Awadalla; Connor P Mulligan; Adam Rokicki; Virginia A Triant; Markella V Zanni; Tomas G Neilan Journal: Am Heart J Date: 2019-01-11 Impact factor: 4.749
Authors: Chris deFilippi; Janet Lo; Robert Christenson; Ida Grundberg; Lauren Stone; Markella V Zanni; Hang Lee; Steven K Grinspoon Journal: AIDS Date: 2018-04-24 Impact factor: 4.177
Authors: Alexandra B Steverson; Anna E Pawlowski; Daniel Schneider; Prasanth Nannapaneni; Jes M Sanders; Chad J Achenbach; Sanjiv J Shah; Donald M Lloyd-Jones; Matthew J Feinstein Journal: Eur J Prev Cardiol Date: 2017-09-25 Impact factor: 7.804
Authors: James D Wilkinson; Paige L Williams; Wendy Yu; Steven D Colan; Armando Mendez; Justin P V Zachariah; Russell B Van Dyke; William T Shearer; Renee E Margossian; Steven E Lipshultz Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Raza M Alvi; Markella V Zanni; Anne M Neilan; Malek Z O Hassan; Noor Tariq; Lili Zhang; Maryam Afshar; Dahlia Banerji; Connor P Mulligan; Adam Rokicki; Magid Awadalla; James L Januzzi; Tomas G Neilan Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079